Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ: LSTA )

4.100 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 4.100
Bid (Size) 3.840 (1)
Ask (Size) 4.500 (15)
Prev. Close 4.100
Today's Range 4.100 - 4.100
52wk Range 2.360 - 9.380
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+58.91%
+58.91%
1 Month
+25.77%
+25.77%
3 Month
+35.31%
+35.31%
6 Month
+17.14%
+17.14%
1 Year
-34.40%
-34.40%

More News

Read More
Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in May
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 30, 2023
Via Benzinga
Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for March 9th
From Virtual Investor Conferences
Via GlobeNewswire
Lisata Therapeutics to Webcast Live at the Life Sciences Investor Forum on March 9th
From Virtual Investor Conferences
Via GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in February
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Lisata Therapeutics Announces Participation in Upcoming Conferences in November 2022
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in October 2022
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Lisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research Award
From Lisata Therapeutics, Inc.
Via GlobeNewswire
121 Stocks That Hit Their 52-Week Low
Via Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.